VistaGen Therapeutics (VTGN) Competitors $3.04 -0.14 (-4.26%) As of 03:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTGN vs. CRVS, IMAB, YMAB, ATXS, VIGL, NBTX, OLMA, FULC, ABEO, and CAPRShould you be buying VistaGen Therapeutics stock or one of its competitors? The main competitors of VistaGen Therapeutics include Corvus Pharmaceuticals (CRVS), I-Mab (IMAB), Y-mAbs Therapeutics (YMAB), Astria Therapeutics (ATXS), Vigil Neuroscience (VIGL), Nanobiotix (NBTX), Olema Pharmaceuticals (OLMA), Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), and Capricor Therapeutics (CAPR). These companies are all part of the "pharmaceutical products" industry. VistaGen Therapeutics vs. Its Competitors Corvus Pharmaceuticals I-Mab Y-mAbs Therapeutics Astria Therapeutics Vigil Neuroscience Nanobiotix Olema Pharmaceuticals Fulcrum Therapeutics Abeona Therapeutics Capricor Therapeutics VistaGen Therapeutics (NASDAQ:VTGN) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation. Do insiders & institutionals believe in VTGN or CRVS? 78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 28.5% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor VTGN or CRVS? In the previous week, VistaGen Therapeutics had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 1 mentions for VistaGen Therapeutics and 0 mentions for Corvus Pharmaceuticals. VistaGen Therapeutics' average media sentiment score of 0.70 beat Corvus Pharmaceuticals' score of 0.00 indicating that VistaGen Therapeutics is being referred to more favorably in the media. Company Overall Sentiment VistaGen Therapeutics Positive Corvus Pharmaceuticals Neutral Which has preferable earnings and valuation, VTGN or CRVS? VistaGen Therapeutics has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVistaGen Therapeutics$646K144.14-$51.42M-$1.78-1.71Corvus PharmaceuticalsN/AN/A-$62.29M-$1.01-5.39 Do analysts recommend VTGN or CRVS? Corvus Pharmaceuticals has a consensus target price of $15.00, indicating a potential upside of 175.48%. Given Corvus Pharmaceuticals' higher probable upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than VistaGen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VistaGen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, VTGN or CRVS? VistaGen Therapeutics has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Is VTGN or CRVS more profitable? Corvus Pharmaceuticals has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -6,777.08%. Corvus Pharmaceuticals' return on equity of -28.61% beat VistaGen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VistaGen Therapeutics-6,777.08% -74.06% -64.10% Corvus Pharmaceuticals N/A -28.61%-18.05% SummaryCorvus Pharmaceuticals beats VistaGen Therapeutics on 8 of the 14 factors compared between the two stocks. Get VistaGen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTGN vs. The Competition Export to ExcelMetricVistaGen TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.96M$3.06B$5.76B$9.75BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-1.7021.0030.8325.91Price / Sales144.14392.25469.77121.46Price / CashN/A43.2325.7828.79Price / Book1.249.739.466.03Net Income-$51.42M-$54.08M$3.27B$265.29M7 Day Performance-10.74%3.12%2.37%2.86%1 Month Performance-1.46%4.57%3.88%1.23%1 Year Performance-17.30%10.22%30.52%19.11% VistaGen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTGNVistaGen Therapeutics1.1303 of 5 stars$3.04-4.3%N/A-13.6%$92.96M$646K-1.7040CRVSCorvus Pharmaceuticals2.3924 of 5 stars$5.32-2.0%$15.00+182.0%+29.1%$404.61MN/A-5.2730IMABI-Mab3.2902 of 5 stars$5.09+4.5%$6.00+17.9%+318.9%$397.69M$3.89M0.00380News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionGap UpYMABY-mAbs Therapeutics2.6829 of 5 stars$8.52flat$9.62+12.9%-37.9%$387.14M$87.68M-17.04150ATXSAstria Therapeutics2.7291 of 5 stars$6.78-1.0%$29.00+327.7%-44.8%$386.58MN/A-3.3730VIGLVigil Neuroscience1.8193 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340NBTXNanobiotix0.7746 of 5 stars$8.80+11.3%$8.00-9.1%+91.1%$379.23M$39.18M0.00100Positive NewsGap DownOLMAOlema Pharmaceuticals1.9815 of 5 stars$5.76+4.5%$24.00+316.7%-51.8%$378.17MN/A-2.9170FULCFulcrum Therapeutics0.9163 of 5 stars$6.64-2.6%$7.57+14.0%-25.0%$368.90M$80M-5.44100ABEOAbeona Therapeutics4.4249 of 5 stars$6.91-3.1%$19.50+182.2%+31.1%$365.62M$3.50M9.8790CAPRCapricor Therapeutics3.0662 of 5 stars$7.70-3.3%$22.56+192.9%+55.7%$363.91M$13.39M-4.70101 Related Companies and Tools Related Companies CRVS Alternatives IMAB Alternatives YMAB Alternatives ATXS Alternatives VIGL Alternatives NBTX Alternatives OLMA Alternatives FULC Alternatives ABEO Alternatives CAPR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTGN) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access